Working… Menu

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01072214
Recruitment Status : Completed
First Posted : February 22, 2010
Last Update Posted : November 14, 2017
Information provided by (Responsible Party):

Brief Summary:
A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will be administered to healthy adult volunteers over a 14-day period with one additional dose given on the 15th day of the session. Three groups of subjects may receive either active drug or placebo (drops without drug). The first group of subjects will receive a maximum of 1.6mg of pazopanib or placebo. The dose of drug to be given to the next two groups will be determined based on the results of the first group of subjects. The last group of subjects will be of Japanese descent.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: pazopanib Drug: Placebo Phase 1

Detailed Description:
The purpose of this study is to characterize the ocular safety and tolerability, the systemic safety and tolerability, and the pharmacokinetic profile of repeat doses of a higher strength ophthalmic formulation of pazopanib, 10 mg/mL. The higher strength formulation provides an opportunity to increase the total daily dose of pazopanib administered. In this 3-cohort study, healthy adult volunteers will participate in one 14-day repeat-dose session (plus a single dose on day 15), randomized to receive either pazopanib eye drops or placebo. Subjects in cohort 1 will receive 1 drop four times daily for a calculated total daily dose of 1.6 mg. The dosage regimen for two subsequent cohorts will be determined based on the emerging safety profile. The Japanese population chosen for the third cohort will provide a safety and tolerability profile as well as the pharmacokinetic profile of pazopanib prior to further development of this formulation in Japanese patients with AMD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-masked, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Repeat Doses of Pazopanib Eye Drops in Healthy Adult Subjects
Actual Study Start Date : March 9, 2010
Actual Primary Completion Date : June 28, 2010
Actual Study Completion Date : June 28, 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Pazopanib

Arm Intervention/treatment
Experimental: 1.6 mg
The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
Drug: pazopanib

Experimental: TBD COHORT 2
Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
Drug: pazopanib

Placebo Comparator: Placebo
Subjects will receive placebo (drops without drug).
Drug: Placebo

Experimental: TBD COHORT 3
Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
Drug: pazopanib

Primary Outcome Measures :
  1. Clinical safety data from AE reporting, clinical observations, physical examinations, vital signs (blood pressure and heart rate), clinical laboratory tests including urinalysis, general ophthalmic examinations, and best-corrected visual acuity tests [ Time Frame: 2 weeks ]
  2. Primary pharmacokinetic endpoints will include: AUC(0-24), Cmax after repeat administration of pazopanib ophthalmic solution, Tmax, and trough steady-state plasma pazopanib concentration (Cτ) [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Secondary pharmacokinetic parameters include: area under the plasma drug concentration versus time curve [AUC(0-t)], observed accumulation ratio (Ro), and apparent terminal half-life (t1/2) after repeat administration will be analyzed [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female ≥ 20 to 64 years of age, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) is confirmatory
  • Body weight ≥ 50 kg for men and ≥ 45 kg for women and body mass index (BMI) within the range 18.5 - 32 kg/m2 (inclusive), where BMI = (weight in kg)/(height in meters)2.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Average QTcF < 450 msec or QTc < 480 msec in subjects with bundle branch block.
  • Best-corrected visual acuity better than 20/80 (Snellen equivalent) in both eyes.

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of clinically relevant coronary heart disease, uncontrolled hypertension, renal disease, diabetes mellitus, impaired endocrine, thyroid, or respiratory function, or psychotic mental illness
  • History of any hemorrhagic event (hemoptysis, cerebral or gastrointestinal) within 6 months of screening
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months of screening.
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • A positive pre-study drug/alcohol screen
  • A positive test for HIV antibody
  • Blood pressure (SBP/DBP) > 140/90 mmHg at screening
  • History of dry eye or presence of any active ocular disease at time of screening that the investigator and medical monitor agree may cause additional risk to the subject or may interfere with study assessments or endpoints
  • Any eye surgery within three months prior to first dose of study medication
  • Use of ocular prescription or non-prescription drugs within 7 days prior to the first dose of study medication
  • Prior history of ocular allergy, unless symptom-free for at least 6 months from first dose.
  • An unwillingness to refrain from wearing contact lenses during the study and up to 2 weeks before the study start
  • History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
  • History of regular alcohol consumption within 6 months of the study defined as:

an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80-proof distilled spirits

  • Participation in a clinical trial where the subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer) prior to the first dose of study medication
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice within 7 days prior to the first dose of study medication
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • Unwillingness or inability to follow the procedures outlined in the protocol
  • For Cohort 3, the following additional inclusion criterion applies:

Subject must have spent most of his or her life in Japan and not have lived outside of Japan for more than 5 years. They must have been born in Japan with four ethnic Japanese grandparents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01072214

Layout table for location information
United States, California
GSK Investigational Site
Glendale, California, United States, 91206
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT01072214     History of Changes
Other Study ID Numbers: 113748
First Posted: February 22, 2010    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions